Sarc
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 40
- Registration Number
- NCT06208748
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 108
- Registration Number
- NCT04967521
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2023-09-18
- Target Recruit Count
- 48
- Registration Number
- NCT04803877
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Cincinnati Children's, Cincinnati, Ohio, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
SARC037: a Phase I/II Study to Evaluate the Safety of Trabectedin in Combination with Irinotecan in Ewing Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 48
- Registration Number
- NCT04067115
- Locations
- 🇺🇸
Boston Children's Hospital / Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2023-12-26
- Target Recruit Count
- 21
- Registration Number
- NCT03433183
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
- Conditions
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2023-11-18
- Target Recruit Count
- 126
- Registration Number
- NCT03092323
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸Mayo Clinic- Florida, Jacksonville, Florida, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
SARC021C: A Continuation Study of TH-CR-406/SARC021
- Conditions
SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)
- Conditions
- Interventions
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2019-01-29
- Target Recruit Count
- 20
- Registration Number
- NCT02303262
- Locations
- 🇺🇸
Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2020-09-29
- Target Recruit Count
- 144
- Registration Number
- NCT02301039
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States